Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

Trial ID or NCT#

NCT02717455

Status

not recruiting iconNOT RECRUITING

Purpose

This phase I trial studies the side effects and best dose of panobinostat in treating younger patients with diffuse intrinsic pontine glioma (DIPG). Panobinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Stratum 1 treats patients with DIPG that has returned or gotten worse (progressed). Stratum 2 treats patients with DIPG or H3K27+Thalamic Diffuse Malignant Glioma (DMG) that has not yet gotten worse. Currently, only Stratum 2 is enrolling patients.

Official Title

Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma

Eligibility Criteria

Ages Eligible for Study: 2 Years to 21 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Michelle Monje
Paul Graham Fisher, MD
Paul Graham Fisher, MD
Neuro-oncologist, Pediatric neurologist
Beirne Family Professor of Pediatric Neuro-Oncology, Professor of Pediatrics and, by courtesy, of Neurosurgery and of Epidemiology and Population Health

Contact us to find out if this trial is right for you.

Contact

Stefania Ursu Chirita
650-723-1423

View on ClinicalTrials.gov